Wall Street Zen Downgrades Pyxis Oncology (NASDAQ:PYXS) to Sell

Pyxis Oncology (NASDAQ:PYXS) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report issued on Friday.

A number of other research firms also recently weighed in on PYXS. Guggenheim began coverage on Pyxis Oncology in a report on Wednesday, September 3rd. They issued a “buy” rating and a $5.00 price objective for the company. HC Wainwright restated a “buy” rating and issued a $5.00 price objective on shares of Pyxis Oncology in a report on Tuesday, August 19th. Weiss Ratings restated a “sell (d-)” rating on shares of Pyxis Oncology in a report on Saturday, September 27th. Finally, Zacks Research upgraded Pyxis Oncology from a “strong sell” rating to a “hold” rating in a report on Monday, August 18th. Four analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $7.75.

Pyxis Oncology Stock Performance

Shares of NASDAQ:PYXS opened at $2.57 on Friday. Pyxis Oncology has a 52-week low of $0.83 and a 52-week high of $5.39. The company has a market capitalization of $159.39 million, a P/E ratio of -1.61 and a beta of 1.33. The company has a 50-day simple moving average of $1.59 and a 200 day simple moving average of $1.29.

Pyxis Oncology (NASDAQ:PYXS) last posted its quarterly earnings data on Thursday, August 14th. The company reported ($0.30) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.06. The company had revenue of $2.82 million during the quarter. As a group, equities analysts forecast that Pyxis Oncology will post -1.04 earnings per share for the current year.

Institutional Investors Weigh In On Pyxis Oncology

Several hedge funds and other institutional investors have recently made changes to their positions in the business. 683 Capital Management LLC increased its position in shares of Pyxis Oncology by 32.5% during the first quarter. 683 Capital Management LLC now owns 550,000 shares of the company’s stock worth $539,000 after acquiring an additional 135,000 shares in the last quarter. Pier 88 Investment Partners LLC increased its position in shares of Pyxis Oncology by 296.6% during the first quarter. Pier 88 Investment Partners LLC now owns 390,960 shares of the company’s stock worth $383,000 after acquiring an additional 292,370 shares in the last quarter. Jane Street Group LLC bought a new stake in shares of Pyxis Oncology during the second quarter worth about $370,000. Schulhoff & Co. Inc. increased its position in shares of Pyxis Oncology by 125.4% during the second quarter. Schulhoff & Co. Inc. now owns 275,000 shares of the company’s stock worth $302,000 after acquiring an additional 153,000 shares in the last quarter. Finally, Marshall Wace LLP bought a new stake in shares of Pyxis Oncology during the second quarter worth about $163,000. 39.09% of the stock is owned by institutional investors.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.